Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$23.88 USD
+0.09 (0.38%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $23.86 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARCT 23.88 +0.09(0.38%)
Will ARCT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARCT
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
Other News for ARCT
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival
Arcturus Therapeutics Enhances Board with Industry Expert Dr. Slaoui
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), BioNTech SE (BNTX) and Tempest Therapeutics (TPST)